We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
New CRISPR/Cas9 License Agreement for ERS Genomics and Cytosurge
Product News

New CRISPR/Cas9 License Agreement for ERS Genomics and Cytosurge

New CRISPR/Cas9 License Agreement for ERS Genomics and Cytosurge
Product News

New CRISPR/Cas9 License Agreement for ERS Genomics and Cytosurge


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "New CRISPR/Cas9 License Agreement for ERS Genomics and Cytosurge "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ERS Genomics Limited ('ERS') is pleased to announce a new license agreement with Cytosurge AG ("Cytosurge"). This is a non-exclusive licensing agreement granting Cytosurge access to the ERS CRISPR/Cas9 patent portfolio.


ERS, co-founded by Dr. Emmanuelle Charpentier, 2020 Nobel Prize winner for gene-editing, provides access to the foundational CRISPR/Cas9 intellectual property. Eighty-nine patents are currently held in over 90 countries.


ERS CEO, Eric Rhodes commented: "CRISPR/Cas9 is a powerful genome engineering tool that has revolutionized biotechnology. We are pleased to support Cytosurge, an exciting and progressive leader in precision single-cell manipulation, in their ongoing developments with this license agreement."


Founded in 2009, Cytosurge AG is a Swiss-based company that develops, manufactures, and distributes state-of-the-art solutions for single-cell research based on its patented FluidFM® technology. These also entail a unique CRISPR cell line engineering service, the FluidFM® CellEDIT Service, that is especially designed for hard-to-transfect cells and complex genome edits. Since edits are made on individual single cells, customers get their monoclonal cell line already in less than 12 weeks.


Dr. Pascal Behr, CEO of Cytosurge, made the following statement: "Our vision as a company is to shift paradigms in single-cell biology and shape the genome revolution to ultimately improve societal health and patient wellbeing. With our newly launched FluidFM® CellEDIT Service we aim to speed up and extend what is currently possible for CRISPR engineered cell lines. The license from ERS is therefore a perfect fit for us."

  

Advertisement